Latest News - AbbVie
Top Corporates Hub
AbbVie
Jim Cramer Says “I Like AstraZeneca Very Much”
03.02.2026 16:34
AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are thinking of selling their position in the stock for profit and buying ABBV shares, Cramer remarked: I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I […]
Silver Economy Boom: Investing in Healthcare's Aging Tailwinds
03.02.2026 16:18
An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
03.02.2026 13:50
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of the Faces of Natrelle® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle® breast implants to help educate, empower, and support others considering breast surgery.
AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion
03.02.2026 13:21
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company has also submitted upadacitinib (RINVOQ) for FDA and EMA review as a potential treatment for vitiligo. For you as an investor, these updates relate to AbbVie’s strategy after Humira's patent expiry to position itself as a broad-based biopharma company with exposure to complex immunology and oncology treatments. The Capstan deal adds a new cell therapy platform, while...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
03.02.2026 13:00
AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV). The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with N
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
03.02.2026 12:55
Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
What Does Wall Street Think About AbbVie Inc. (ABBV)?
03.02.2026 09:34
AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to invest in. On January 27, Citi cut the price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while maintaining a Neutral rating on the shares. The firm told investors that it adjusted price targets in the biopharma group as part […]
AbbVie (ABBV) Q4 Earnings: What To Expect
03.02.2026 03:17
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Wednesday before market open. Here’s what to expect.
AbbVie Inc. (ABBV): A Bull Case Theory
03.02.2026 00:28
We came across a bullish thesis on AbbVie Inc. on Disruptive Analytics ’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $223.01 as of January 30th. ABBV’s trailing and forward P/E were 166.99 and 15.70 respectively according to Yahoo Finance. AbbVie Inc., a research-based biopharmaceutical […]
Where Will AbbVie Be in 5 Years?
02.02.2026 09:05
A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.
AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth
31.01.2026 14:35
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for 2026. On January 28, Goldman Sachs reaffirmed its Neutral rating and $223 price target on AbbVie Inc. (NYSE:ABBV) ahead of its Q4 2025 earnings and 2026 guidance release. The firm expects healthy growth, projecting $67.1 billion in revenue, $21.3 billion from Skyrizi, […]
Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma
31.01.2026 13:31
AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Stocks to Buy for the Long Term. On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm’s broader Q4 review of the biopharma space. In its […]
AbbVie’s US$100b Pledge Raises Questions On Value, Margins And Debt
31.01.2026 05:12
AbbVie (NYSE:ABBV) has entered a voluntary agreement with the U.S. government to commit US$100b to U.S. research and development and capital investments over the next decade. The company is also launching a three year effort focused on lowering drug prices while expanding U.S. manufacturing and direct to patient care access. AbbVie is a large U.S. based pharmaceutical company with a portfolio that spans immunology, oncology and other therapeutic areas. The new commitment sits against a...
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)
30.01.2026 07:07
Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found […]
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
29.01.2026 13:00
AbbVie (NYSE: ABBV) announced today the launch of Love in Mind™, an educational initiative that seeks to elevate the conversation about the emotional impact of living with migraine, beyond the physical symptoms, with a focus on dating and romantic relationships. Migraine is more than just a headache. It is an underdiagnosed, undertreated neurological disease that can cause debilitating pain affecting nearly 40 million Americans.1,2
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
28.01.2026 13:00
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.
Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
28.01.2026 01:04
AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...
Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum
27.01.2026 07:16
AbbVie Inc. (NYSE:ABBV) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Berenberg raised its price target on AbbVie Inc. (NYSE:ABBV) to $275 from $270, while keeping a Buy rating on the stock. The firm said it is feeling more confident about AbbVie’s outlook, especially after lifting […]
How Recent Price Target Rethinks Are Rewriting The Story For AbbVie (ABBV)
26.01.2026 16:21
AbbVie is back in focus after a fresh price target update, putting the spotlight on how investors are reassessing the story behind the stock. With the target shifting from None to None, the core question is what has changed in the narrative, not just in the number. Stay tuned to see how you can keep on top of these evolving views and what they might mean for how you follow AbbVie in the future. Stay updated as the Fair Value for AbbVie shifts by adding it to your watchlist or portfolio...
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
26.01.2026 14:00
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.